Search

Displaying results 5071 - 5080 of 10000 in total
  1. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10597
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10776
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10777
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10778
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10802
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen

    go.drugbank.com/drugs/DB11036
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  8. Drug

    AM365

    go.drugbank.com/drugs/DB06564
    Experimental

    Detiviciclovir (AM365) is an antiviral nucleoside analogue.

  9. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

  10. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.